Synergism between chemotherapy and immune responses has been evidenced in animals and man. In addition, non-specific immunostimulation seems to increase the efficiency of anticancer chemotherapy. Up to now most of the clinical trials have been conducted applying immunoadjuvants after initial chemotherapeutic treatment. Since presensitized immunocompetent cells are more radio- and chemo-resistant than non-stimulated lymphocytes, a trial of immunostimulation before chemotherapy is based on rational experimental basis. Such program, activated in humans during 1976, is conducted according to the following general scheme:o1.Chemotherapy alone2.Chemotherapy followed by BCG and recycle3.Chemotherapy preceded and followed by BCG and recycle. Protocols for breast, lung, colorectal and ovarian cancer treatment are described.
ASJC Scopus subject areas